Researchers say if their results are confirmed through further study they are optimistic the approach could be used to treat chronic infections for the first time.

In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able to establish infection of liver cells, research led by Memorial Sloan Kettering Cancer Center ...

In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able to establish ...

Nucleoside analogs are transformative in cancer and antiviral therapies, offering new avenues for treatment despite ...

Deep Track, a Greenwich, Ct., investment management company that holds 13.5% of Dynavax's stock, pointed its finger at ...

The trial was tailored to evaluate the therapy at multiple ascending dose levels, with three dose administrations per level.

Precision BioSciences reports early PBGENE-HBV trial data showing safety and antiviral activity in chronic Hepatitis B patients, with more results expected in 2025.

Dynavax Technologies (NASDAQ:DVAX – Get Free Report) was downgraded by equities researchers at The Goldman Sachs Group from a “neutral” rating to a “sell” rating in a research report issued on Tuesday ...

This guide includes an overview of practices for the prevention and management of sexually transmitted and blood-borne infections (STBBI) by healthcare professionals practicing in public health or ...

Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments.

Goldman Sachs downgraded Dynavax to Sell, citing increased competition in the shingles vaccine market and uncertainty over hepatitis B revaccination demand.

With several drugs in use that inhibit the hepatitis B virus polymerases (nucleos(t)ide analogues (or NUCs)), some argue that new direct-acting antiviral drugs, and new NUCs in particular ...